
==== Front
Neuropsychopharmacology
Neuropsychopharmacology
Neuropsychopharmacology
0893-133X
1740-634X
Springer International Publishing Cham

38822128
1884
10.1038/s41386-024-01884-5
Article
Local and global effects of sedation in resting-state fMRI: a randomized, placebo-controlled comparison between etifoxine and alprazolam
http://orcid.org/0000-0001-9366-2406
Wein Simon
Riebel Marco
Seidel Philipp
Brunner Lisa-Marie
Wagner Viola
Nothdurfter Caroline
Rupprecht Rainer
http://orcid.org/0000-0002-0303-6979
Schwarzbach Jens V. Jens.Schwarzbach@ukr.de

https://ror.org/01eezs655 grid.7727.5 0000 0001 2190 5763 Department of Psychiatry and Psychotherapy, University of Regensburg, Universitätsstrasse 84, Regensburg, 93053 Germany
31 5 2024
31 5 2024
10 2024
49 11 17381748
19 9 2023
29 4 2024
2 5 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article–s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article–s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
TSPO ligands are promising alternatives to benzodiazepines in the treatment of anxiety, as they display less pronounced side effects such as sedation, cognitive impairment, tolerance development and abuse potential. In a randomized double-blind repeated-measures study we compare a benzodiazepine (alprazolam) to a TSPO ligand (etifoxine) by assessing side effects and acquiring resting-state fMRI data from 34 healthy participants after 5 days of taking alprazolam, etifoxine or a placebo. To study the effects of the pharmacological interventions in fMRI in detail and across different scales, we combine in our study complementary analysis strategies related to whole-brain functional network connectivity, local connectivity analysis expressed in regional homogeneity, fluctuations in low-frequency BOLD amplitudes and coherency of independent resting-state networks. Participants reported considerable adverse effects such as fatigue, sleepiness and concentration impairments, related to the administration of alprazolam compared to placebo. In resting-state fMRI we found a significant decrease in functional connection density, network efficiency and a decrease in the networks rich-club coefficient related to alprazolam. While observing a general decrease in regional homogeneity in high-level brain networks in the alprazolam condition, we simultaneously could detect an increase in regional homogeneity and resting-state network coherence in low-level sensory regions. Further we found a general increase in the low-frequency compartment of the BOLD signal. In the etifoxine condition, participants did not report any significant side effects compared to the placebo, and we did not observe any corresponding modulations in our fMRI metrics. Our results are consistent with the idea that sedation globally disconnects low-level functional networks, but simultaneously increases their within-connectivity. Further, our results point towards the potential of TSPO ligands in the treatment of anxiety and depression.

Subject terms

Neuroscience
Medical research
https://doi.org/10.13039/501100001659 Deutsche Forschungsgemeinschaft (German Research Foundation) 422179811 422179811 422179811 Nothdurfter Caroline Rupprecht Rainer Schwarzbach Jens V. issue-copyright-statement© American College of Neuropsychopharmacology 2024
==== Body
pmcIntroduction

Benzodiazepines are highly effective in treating stress-related conditions due to their potent and fast-working anxiolytic properties via positive allosteric modulations on α and γ binding sites of the GABAA receptor [1, 2]. However, benzodiazepines exhibit short and long-term side effects, such as sedation, cognitive impairment as well as tolerance and abuse potential [3–5]. Consequently, pharmacological alternatives are needed for clinical practice. Etifoxine targets α2-containing GABAA receptors subunits, binds to the translocator protein (18 kDa) (TSPO) and putatively acts via the formation of endogenous neurosteroids [6]. Thereby it may constitute such an alternative as it creates fewer and less pronounced side effects while being comparatively effective in terms of reducing anxiety [7–10]. Neurosteroids, if applied exogenously, e.g. in form of brexanolone and zuranolone, have recently shown promise in quickly alleviating postpartum and major depressive disorder symptoms [11, 12]. The clinical anxiolytic efficacy and non-inferiority compared to benzodiazepines has been addressed in several studies where etifoxine showed fewer disruptive side effects like sedation and cognitive impairment [7, 8, 13]. The impact of the drug on neural networks and how this may yield such a seemingly more favorable side effect spectrum is yet unknown [2, 14].

Resting-state fMRI (rs-fMRI) can track changes in brain networks related to pharmacologically induced modulations [15, 16]. Administering chloral hydrate, dexmedetomidine and propofol revealed decreases in connection density and efficiency in whole-brain networks during anaesthesia in rs-fMRI [17–19]. In a study of localized functional connectivity in rs-fMRI administering alprazolam 1.5 hrs before measurement increased local activity coherence in sensory- and sensory-integration areas [20]. Administering diazepam for 7 and 8 days (last dose 1 h before measurement) [21] or midazolam intravenous during measurement [22] yielded an increase of within-network connectivity mainly in low-level sensory networks. Additionally, midazolam in adults and thiopental in children elevated low-frequency amplitudes (<0.05 Hz) in the visual, sensorimotor and auditory resting-state network during intravenous application [23, 24]. Within the default network reduced functional connectivity in the posterior cingulate cortex was reported during sedation [25]. A review of midazolam effects summarized that altered consciousness with midazolam is, in general, accompanied by decreased cerebral blood flow in the thalami and in precuneus regions [15]. Moreover, it is hypothesized that sedation with midazolam mainly alters functional connectivity in higher-order brain areas while areas concerned with primary sensory functions tend to remain unaffected, or even display elevated within-network connectivity [22].

In our study we used rs-fMRI and behavioural assessments to compare neural correlates and side effects elicited by a TSPO ligand (etifoxine) and a benzodiazepine (alprazolam) in a three-armed, double-blind, placebo-controlled repeated-measures study. We compared modulatory effects of alprazolam, etifoxine, and a placebo with respect to a baseline measurement at the beginning of the study. We employed optimized multi-band fMRI sequences [26] and combined several different rs-fMRI analysis strategies to study their effects at high spatiotemporal resolution and across different scales. We investigated alterations of the functional network properties on a whole-brain level and subsequently explored how treatments differentially modulate connectivity individual brain regions [27]. We then studied changes in local connectivity by means of regional homogeneity (ReHo) [28] and examined localized modulations in fractional amplitude of low-frequency fluctuations (fALFF) of the BOLD signal [29]. Finally, we incorporated independent component analysis (ICA), a multivariate and data-driven technique to extract individualized resting-state networks [30], to study changes of within-network BOLD activity synchronization.

Materials and methods

Study participants

34 healthy male participants between the age of 18 and 55 years participated in this study (Table S1). Because it was the first neuroimaging study including etifoxine, we were not able to estimate an effect size in advance and the number of participants was selected based on practical constraints including study duration and throughput of participants. All participants were screened by a physician for the absence of physical and psychiatric disorders by physical examination and the German version of the Mini-International Neuropsychiatric Interview (MINI) [31].

Study design

We performed a double-blind, placebo-controlled study using a repeated-measures design with fully balanced order of treatments to mitigate potential carry-over effects (trial registration: https://drks.de/search/de/trial/DRKS00020267). The study was approved by the local ethics committee (approval number 18-1197-111) and the National Institute for Pharmaceutical Security (BfArM, Eudra-CT-number: 2018-002181-40). Participants gave their written informed consent at the beginning of the experiment. Data was collected during the period 06.07.2020–17.12.2021. Subjects underwent four measurement sessions in total, starting with a baseline followed by a pseudo-randomly assigned counterbalanced medication intake of placebo, alprazolam (1.5 mg/d in 3 doses of 0.5 mg) or etifoxine (150 mg/d in 3 doses of 50 mg) for 5 days, each with at least 7 days washout phases between medications. Based on known kinetics of etifoxine and alprazolam (respective half-life times: 20 h for active metabolite of etifoxine and 15 h for alprazolam) more than 98% of the respective substance should be eliminated after six days [32], yielding negligible carry-over effects mitigated by counterbalancing. Subjects ingested the last dose at 12:00 a.m. of treatment day 5 and underwent fMRI measurement 1 h later (maximum plasma levels of etifoxine and alprazolam are expected after maximum 2 h). Based on pharmacokinetic assumptions relative serum levels at the start of the MRI session accumulate within 5 days to ~342 % (equivalent to 171 mg oral dose) for etifoxine and ~274 % (equivalent to 1.37 mg oral dose) for alprazolam. Order of treatment (placebo, alprazolam, etifoxine) was fully counterbalanced, yielding groups of six participants for each of the six possible orders. The random allocation sequence was generated using SAS 9.4 and the procedure proc plan by the Center for Clinical Trials of the University Hospital Regensburg. Since we only included 34 participants, two sequences were only realized five out of six times, as shown in the CONSORT flow diagram in Fig. S1.

All members of the study personnel enrolled participants, and all participants were assigned to all medications in this repeated measurement design. During the period of the study, neither participants nor study personal knew about the assignment of medication, which was delivered in numbered containers. The study participants were instructed to refrain from consuming alcohol, operating a car or heavy machinery, from smoking more than 5 cigarettes per day, and from consuming caffeine prior to the fMRI session.

Self-reported side effects

Each day of medication, 1.5 h after intake, participants were required to report side effects. These side effects included dizziness, skin reactions, changes in appetite (either decreased or increased), confusion, hallucinations, tantrums, sleeplessness, nervousness, headaches, constipation, nausea, vertigo, inner restlessness, sleepiness, concentration problems, alterations in libido, and fatigue. Participants used a rating scale from 0 (no side effect) to 3 (strong side effect) to indicate the severity of these symptoms.

MRI acquisition

Functional MRI data were collected with a Siemens Magnetom Prisma 3T Scanner at the University of Regensburg. Participants were instructed to relax and stay awake during the resting-state fMRI (rs-fMRI) session, while keeping their eyes closed. Based on pre-studies on optimizing the signal to noise ratio of echoplanar imaging (EPI) protocols [26], we used an EPI multi-band sequence (multi-band factor 4) with a repetition time (TR) of 1000 ms, echo time (TE) of 30 ms and a flip angle (FA) of 6° for acquiring functional images. During a scanning time of 22 min in total 1320 volumes were collected, with a field of view (FoV) of 192 mm × 192 mm, an acquisition matrix (AM) of 64 × 64, and an isotropic voxel size of 3 mm. Field map images were collected by using a double-echo spoiled gradient echo sequence, with TR = 715 ms, TE = 5.81/8.27 ms, FA = 40°, with an isotropic voxel size of 3 mm, generating a magnitude image and two-phase images. High-resolution T1-weighted images were acquired using a Magnetization Prepared Rapid Gradient Echo (MP-RAGE) sequence, with a TR = 1919 ms, TE = 3.67 ms, FA = 9°, AM = 256 × 256 and FoV = 250 mm × 250 mm.

MRI preprocessing

For processing the functional and structural imaging data, we used the processing pipeline provided by fMRIPrep1 (version 20.2.4) [33] which included bias field correction, motion correction based on MCFLIRT [34], slice timing correction and projection onto the cortical surface, generating high-resolution grayordinate time courses in the symmetric fsLR standard space [35]. A summary of the detailed fMRIPrep preprocessing steps is provided in supplement II. Prior to the ReHo, fALFF and ICA analysis we smoothed the fMRI data using Gaussian surface smoothing with a FWHM of 3 mm [35].

Brain connectivity analysis

We first studied differences in resting-state functional connectivity (FC) on the whole-brain level between different pharmacological treatments. We subdivided each hemisphere into 180 regions of interest (ROIs) defined by Glasser et al. [36] and computed the average activity time course within each region and filtered the resting-state BOLD signal within the 0.01 Hz - 0.1 Hz low-frequency range. FC strength was computed with the Pearson correlation coefficient between time courses of pairs of regions to obtain a 360 × 360 FC matrix for each rs-fMRI session that was thresholded at different levels σ to obtained a binarized connectivity matrix (σ = [0.5, 0.6, 0.7]), yielding a range of reasonable and discriminative functional connectivity densities (on average 55.9%, 39.2%, and 22.0% of possible connections, respectively). This workflow is illustrated in Fig. 1A. Our goal was to study differences in functional brain networks by analyzing their graph theoretical properties such as edge density, as well as global and local network efficiency [27]. Additionally we studied the interconnectedness of high-degree nodes by analyzing the rich-club coefficient of the network [37]. While these graph measures reflect changes of the functional network on the whole-brain level, we additionally investigated in more detail alterations in connectivity of individual areas. For this purpose we also computed edge density, average connection efficiency and betweeness centrality of each brain region [27]. A detailed definition of these network metrics is additionally provided in Supplement I.Fig. 1 Analysis strategies used in our study to characterize activity dynamics in rs-fMRI.

A illustrates how resting-state FC between different ROIs was computed. We used an atlas to subdivide the cortex into segregated ROIs and correlated the average BOLD time courses within each ROI, yielding a functional connectivity matrix. Using different graph theoretical measures allowed us to analyze changes of the region-wise or whole-brain connectivity. B shows how ReHo maps were derived from rs-fMRI data. For each vertex on the surface the neighbouring vertices within a pre-defined radius were selected to define a local neighbourhood (marked in blue in this example). By computing the similarity between all time courses within this neighbourhood, we obtained a ReHo value for each vertex on the surface. C illustrates the steps to compute a fALFF map from rs-fMRI data. For each vertex, the power spectrum of its BOLD time course was computed, and fALLF resulted from the ratio of the low-frequency power to the power of the entire frequency range. D shows the basic principle of ICA of rs-fMRI data. Spatial-temporal activity maps acquired during a session at different timepoints (t) were decomposed by ICA into a set of spatially independent components (ICs), representing coherently activated resting-state networks.

Regional homogeneity

While classical FC analysis offers us a possibility to study long-distance relationships between segregated brain areas, regional homogeneity (ReHo) can supplement such analysis by quantifying local connectivity across the cortex at a scale of millimetres [28]. In fMRI, ReHo is defined as the temporal coherence or synchrony of the BOLD signal of neighbouring voxels or vertices. We implemented a surface-based approach, selecting for each vertex its k-hop neighbouring vertices in the fsLR standard space [35], and quantified ReHo by computing the average Pearson correlation between these neighbouring BOLD time courses (Fig. 1B). This metric allowed us to study the changes in coherence of spontaneous resting-state activity between different treatments.

Low-frequency fluctuations

Classical connectivity-based analysis does not directly provide us with information on amplitudes of brain activity in fMRI. To account for this shortcoming we additionally investigated alterations in the fractional amplitude of low-frequency fluctuations (fALFF) [29, 38]. This metric is based on the ratio of the BOLD signal’s power spectrum of low frequencies to the signal’s entire frequency range. We focused on the very-low-frequency range 0.01–0.05 Hz, which has been reported to increase during midazolam sedation and anaesthesia [23, 24, 30]. For each vertex of the surface in fsLR standard space [35] we computed the corresponding frequency spectrum (Fig. 1C) and analyzed the localized differences of related fALFF values between different medication groups.

Independent component analysis

Independent component analysis (ICA) is a multivariate data-driven technique [23, 39] that aims to explain spatial-temporal fMRI data by a set of coherently fluctuating source components of BOLD activity, representing spatially independent brain networks (Fig. 1D). Due to inherent ambiguities in the canonical ICA model, it is not straightforward to apply this technique for group studies [40–42]. Constrained ICA (cICA) offers a robust and well-defined approach for extracting independent resting-state networks on the subject-level, which are consistent across a group of subjects and therefore allow for group inferences [43]. Besides maximizing non-Gaussianity of estimated source networks, cICA simultaneously optimizes the similarity to a reference component to obtain well-defined and consistent components across subjects. We used the 9 cortical high-resolution resting-state networks2 [44] as reference components for cICA. This yielded 9 resting-state networks per subject and per intervention, allowing us to compare these spatial patterns between different medications. Prior to cICA we applied a low-pass filter with a cutoff frequency at 0.2 Hz to the BOLD timecourses. A detailed description of the cICA model and optimization procedure is provided is provided in Supplement I.

Results

Self-reported side effects

Figure 2 shows intensity scores and their respective confidence intervals for side effect-related symptoms grouped by medication and intervention. There were considerable side effects such as fatigue, sleepiness, concentration impairment, dizziness and confusion in particular related to the administration of alprazolam. For statistical testing we computed a paired t-test and applied false discovery rate (FDR) correction with q ≤ 0.05 to account for multiple comparisons [45]. Differential effects between alprazolam, etifoxine, and placebo are indicated by pairwise comparisons at the top of Fig. 2. Respective p values and effect sizes are listed in Supplement I table S2.Fig. 2 Results of the side effects questionnaire for the different interventions.

Alprazolam produced stronger side effects such as fatigue, sleepiness, concentration impairment, dizziness, and confusion compared to etifoxine and placebo. Error bars represent 95% confidence intervals across subjects. Significant differences between treatments: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, ns not significant, (ns) not significant after false discovery rate correction.

MRI results

In our first analysis we studied differences of the functional brain network at a global level by comparing whole-brain edge densities of FC networks between baseline and the three different interventions. Figure 3A–C illustrates edge density, local efficiency and global efficiency of the FC network for the baseline-, placebo-, alprazolam- and etifoxine conditions respectively, for three different connectivity thresholds σ. For each rs-fMRI session we computed the corresponding graph measure and applied a paired t-test between fMRI sessions with different medications, including FDR correction (q ≤ 0.05) to control for multiple comparisons [45]. In addition, we analyzed the rich-club coefficient of the whole-brain network in Fig. 3D. For each degree cutoff k of the rich-club coefficient we applied a paired t-test and used FDR correction to account for comparing multiple groups. We analyzed the rich-club coefficient up to a maximum degree cutoff k where this metric could be computed for all 34 subjects. To account for testing this metric across various degree cutoffs k, we applied principal component analysis and tested for differences in individual loadings of this metric on the first principal component [46], since the values are highly correlated (explaining 91.9%, 93.0%, and 87.8% of the variance for the thresholds σ = [0.5, 0.6, 0.7] respectively).Fig. 3 A–C Average edge density, global efficiency and local efficiency of the FC network under different medications andl for different correlation thresholds σ. We found reduced edge density and reduced global and local efficiency in the alprazolam condition compared to baseline, and the placebo and etifoxine conditions. In (D) a reduction of the rich-club coefficient due to administration of alprazolam can be observed. Regions, where the difference to alprazolam becomes significant, are indicated in bars above, with the respective colours for the placebo, etifoxine and baseline condition. Error bars represent 95% confidence intervals across subjects. Significant differences between conditions in (A–C): *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ns not significant, (ns): not significant after false discovery rate correction. Bars in (D) indicate regions where a significant difference to alprazolam can be observed with p ≤ 0.05.

We further preliminary explored the direct relationship between self-reported side effects and modulations in resting-state connectivity in Fig. S2. Subjects that reported stronger side effects showed a consistent but not significant tendency of reduced FC edge density, and reduced global and local efficiency.

As shown in Fig. 3A we mainly observe a significantly reduced functional edge density in the alprazolam condition, compared to the baseline, and to treatment with placebo or etifoxine. Similarly we found a tendency of reduced local and global efficiency due to alprazolam, as depicted in Fig. 3B, C, while observing no such down-modulation effects in the etifoxine condition. Figure 3D shows a significantly reduced rich-club coefficient in the alprazolam condition in comparison to the placebo, etifoxine and baseline condition for the vast majority of degree cutoffs k (regions with significant differences p ≤ 0.05 to the alprazolam condition are indicated with bars on top of the graphs). We also found an overall significant difference (p ≤ 0.05) in principal component loadings between alprazolam and all other conditions for all thresholds σ. We found no significant modulation of the rich-club coefficient in the etifoxine condition.

We then studied regional differences in functional markers between interventions and investigated differences in ROI connectivity degree, ReHo, as well as modulations in fALFF. To test for differences in those metrics between groups we employed a paired t-test and used FDR correction (q ≤ 0.05) to account for comparing multiple ROIs or vertices [45]. Figure 4A shows those regions of the multi-modal parcellation atlas [36] that significantly differed in connectivity degree after administering alprazolam compared to placebo. For this comparison we selected a moderate FC threshold of σ = 0.6. We observed a significant decrease in FC mainly in the superior temporal gyrus (regions A5, STSdp as described by Glasser et al. [36]), inferior parietal lobule (PGi, PGs), intraparietal sulcus (LIPd, LIPv), inferior frontal gyrus (IFSp) and middle temporal cortex (MT, MST, FST, PH). Figure 4B depicts regions that were significantly altered in their local connectivity characterized by ReHo. To compute ReHo we employed a medium-sized neighbourhood radius of 4 vertices (≈5.2 mm) in this comparison, but additionally provide results, illustrated in Fig. S4, when using a smaller neighbourhood consisting of only 2 vertices (≈2.6 mm). We found a decrease in ReHo mainly in the inferior parietal lobule (PGs, PFm), right precentral sulcus (R 6v), right inferior frontal sulcus (R IFSa), and occipital lobe (LO1, LO2, V4, V4t). Interestingly, we observed a reversed effect of increased ReHo in the precentral gyrus/primary motor cortex (4). Local differences in the low-frequency amplitudes based on fALFF are shown in Fig. 4C. For this metric we found mainly increased fALFF ranging from the middle temporal cortex (MT, MST) to the occipital lobe (V1, V2, V3) and parieto-occipital sulcus (POS1, POS2), and also in the external cingulate gyrus (p32), anterior midcingulate cortex (a32pr), inferior frontal sulcus (IFSa, a9-46v), and precentral gyrus/primary motor cortex (4). We further investigated localized differences in resting-state networks extracted by ICA. We selected all vertices within one resting-state network by thresholding the z-maps with ∣z∣ ≥ 2 and using a paired t-test (FDR corrected with q ≤ 0.05) to test for differences in these networks related to intervention. In the comparison between placebo and alprazolam we found significant differences in 3 out of 9 resting-state networks. Figure 4D shows the significantly different spatial areas of all 3 networks projected onto one cortical surface for convenience. The average resting-state networks (thresholded at ∣z∣ ≥ 2) across subjects are illustrated in the background in green, while locations with significantly higher/lower connectivity are highlighted in red/blue in this figure. In this comparison we observed an increase in the BOLD activity coherence in the superior temporal cortex (A6), in the right primary somatosensory cortex (R 1) and in the primary visual cortex (V1).Fig. 4 Comparison of rs-fMRI measures between alprazolam and placebo.

The first row (A) shows the regions in the left (L) and right (R) hemisphere where FC degree was significantly lower after administering alprazolam compared to placebo. The second row (B) depicts several regions in which local connectivity, as defined by ReHo, was lower after administering alprazolam compared to placebo, except for one region in superior/medial aspects of somato-motor cortex. The third row (C) shows that low-frequency amplitudes, as derived from fALFF, were higher after administering alprazolam compared to placebo. The fourth row (D) illustrates alterations in ICA-based resting-state networks, which display higher connectivity after the administration of alprazolam within the temporal, occipital and right somatosensory cortex. Yellow and blue colours depict t-values (from blue, alprazolam < placebo, to yellow, alprazolam > placebo).

In a comparison between alprazolam and etifoxine we found modulatory effects of connectivity degree, ReHo and fALFF spatially similar but more pronounced to the rs-fMRI metrics reported above. As shown in Fig. 5A we found lower FC for the alprazolam treatment mainly in the superior temporal gyrus (A4, A5, STV, STSdp, STSda), inferior parietal lobule (PGi, PGs), precentral and postcentral gyrus (1, 2, 3a, 3b, 4), and ranging from the occipital (V1, V2, V3) to the medial temporal lobe (MT, FST, MST, PH). Also, we noticed considerably lower FC in the inferior frontal gyrus (IFSp, 45), whereby these differences in FC strength appeared more pronounced than in the aprazolam-placebo comparison. Furthermore, as illustrated in Fig. 5B, we detected a decrease in ReHo after administering aprazolam compared to etifoxine, mainly in the inferior parietal lobule (PGs, PGi, PFop), lateral occiptal complex of the occipital lobe (PHT, FST), occipital lobe (LO1, LO2, V4, V4t), precentral sulcus (6v), inferior frontal sulcus (IFSa, IFSp, 44, 45), and posterior cingulate cortex (7m, 31pd, 31pv). We also observed a significant increase in ReHo in the precentral gyrus/primary motor cortex (4). Figure 5C shows increased low-frequency oscillations raining from the occipital lobe (V1, V2) to the middle temporal cortex (MT, MST), parieto-occipital sulcus (POS1, POS2), external cingulate gyrus (p32), precentral gyrus/primary motor cortex (4), and posterior cingulate cortex (23c, 24dd, 5mv). As illustrated in Fig. 5D, we also found differences in connectivity of 3 resting-state networks, which showed increased coherence in the superior temporal cortex (A6), right primary somatosensory cortex (R 1) and in the primary visual cortex (V1).Fig. 5 Comparison of rs-fMRI measures between alprazolam and etifoxine.

The first row (A) shows that FC degree was significantly lower after administering alprazolam compared to etifoxine. The second row (B) depicts several regions in which local connectivity, as defined by ReHo, was lower after administering alprazolam compared to etifoxine. The third row (C) shows that low-frequency amplitudes, as derived from fALFF, were higher after administering alprazolam compared to etifoxine. The fourth row (D) illustrates alterations in ICA based resting-state networks, which show higher coherence in the alprazolam condition in the temporal, occipital and right somatosensory cortex. Yellow and blue colours depict t-values (from blue, alprazolam < etifoxine, to yellow, alprazolam > etifoxine).

A comparison between alprazolam and the baseline condition is shown in Fig. S3. Here we also found a significant decrease of ROI degree for the majority of brain regions (Fig. S3A). Similar to the comparison to the placebo group, we observe mainly a decrease of ReHo (Fig. S3B), but simultaneously an increase in the precentral gyrus/primary motor cortex (4) and parieto-occipital sulcus (ProS, PreS). Further we also detect strongly increased fALFF values in the alprazolam session in comparison to the baseline condition (Fig. S3C) and found increased resting-state network coherence in low-level sensory networks (Fig. S3D). To relate these regions altered by treatment with alprazolam to commonly observed resting-state networks, we provide an overlay of all modulations with the 7 resting-state networks defined by Yeo et al. [47] in Figs. S8, S9 and S10.

In addition to analyzing differences in the connectivity degree of ROIs within the functional network, we also studied changes in the connectivity efficiency, as shown in Fig. S5. Here we observed a downmodulation of connection efficiency after administering alprazolam, wherein differences were the strongest in comparison to the etifoxine condition. As shown in Fig. S6 we found an increase in the betweenness centrality in the alprazolam condition in comparison to etifoxine in the middle (6, R FEF) and right superior frontal gyrus (R SFL, R 8BL), including the right occipital cortex (R LO1).

We observed an increase fALFF between etifoxine and baseline in left anterior cingulate and right orbitofrontal cortices (see Supplementary Fig. S7). However, we did not find such differences in our critical comparison etifoxine vs. placebo. We did not find any significant differences between the placebo and baseline conditions.

Discussion

Summary of findings

In this double-blind and placebo-controlled study, we used a repeated-measures design and rs-fMRI to investigate side effects and the neural correlates of a benzodiazepine (alprazolam) in comparison to a TSPO ligand (etifoxine). After administering alprazolam, we observed a considerable increase in fatigue, sleepiness, concentration problems, dizziness, and confusion, all of which are well-known side effects of benzodiazepines [3–5], which we did not find in the etifoxine condition.

To study the neural correlates of these interventions we analyzed the impact of alprazolam and etifoxine on whole-brain functional connectivity in comparison to the placebo- and baseline conditions. We observed a considerable decrease of connection density after the administration of alprazolam. Comparable decrease in whole-brain connectivity has been reported in rs-fMRI after sedation with chloral hydrate and dexmedetomidine [17, 18] and using nitrous oxide in electroencephalography [48]. The decrease of the rich-club coefficient in the alprazolam condition points out that also highly connected brain regions lose their interconnectedness. We studied in more detail regional effects of medication in terms of global connectivity. We observed decreases in connection degree and connection efficiency mainly in the inferior parietal lobule, middle frontal gyrus, postcentral gyrus and occipital lobe after administration of alprazolam in comparison to the other three conditions. Changes in the network topology under alprazolam were reflected in an increase in betweenness centrality mainly in the middle and superior frontal cortex in comparison to etifoxine. We further preliminarily explored direct relationships between FC and side effect strengths. We found that subjects that reported stronger side effects showed a consistent but not significant tendency of reduced FC edge density, and reduced global and local efficiency. To investigate this relationship in more depth, it probably would have been necessary to stronger sedate the subjects to achieve a larger range of side effects strengths, what might be interesting for future studies.

We subsequently analyzed differences in local connectivity and found a decrease in ReHo mainly in the inferior parietal lobule, precentral sulcus, inferior frontal sulcus, and occipital lobe after administration of alprazolam. Interestingly, we observed increases in ReHo in the precentral gyrus/primary motor cortex. A recent rs-fMRI study on alprazolam [20] found, similar to our results, increased local connectivity in sensorimotor cortex, but also in visual cortices. This latter difference to our findings could be due to procedural differences as participants of our study underwent rs-fMRI with their eyes closed. It is known that ReHo in the visual system is sensitive to participants having their eyes open or closed in rs-fMRI [49, 50]. We additionally found a decrease in local connectivity within frontal and parietal cortices what might be attributed to a functionally clearer definition of local neighbourhoods based on the cortex surface [28], as well as using multi-band EPI sequences, including fieldmaps, for optimizing analysis sensitivity [26].

Further, we found increased fALFF in the occipital lobe, parieto-occipital sulcus, precentral gyrus and posterior cingulate cortex related to the administration of alprazolam. Such an increase of in the very-low BOLD signal frequency range <0.05 Hz has also been observed in sedation related to anaesthesia and to the administration of midazolam in studies of Kiviniemi et al. [23, 24, 30] mainly in visual, sensorimotor and auditory resting-state networks.

Finally, we incorporated a multivariate ICA approach to assess brain network specific alterations. Similar to rs-fMRI studies on midazolam [21, 22], ICA revealed increased within-network coherence in the alprazolam condition compared to the placebo, etifoxine and baseline conditions in regions belonging to low-level sensory systems such as primary visual and superior temporal and in the primary somatosensory cortex. Our findings on alprazolam therefore align with the results of those studies and support the idea of higher coherence within sensory networks related to sedation.

These results need to be discussed in light of possible limitations. A larger number of subjects might have improved the sensitivity for etifoxine-related effects. However, the use of a repeated-measures design should mitigate decremental effects on power. In addition, the study design was optimized to detect differences in the rs-fMRI measures and self-reported side effects respectively. Analysis of potential correlations between resting-state measure changes and adverse effects beyond this level must remain exploratory. Further research building on these findings and addressing the relationship between the neural measures and side effects could include objective measures of side effects, such as concentration tests, and attempt to establish a dose-dependent relationship. Finally, for the safety of the participants, the drug dose was titrated to a moderate level, resulting in only modest behavioural effects. Therefore, conclusive evidence for behavioural correlates of the demonstrated pharmacologically induced neural effects can only be provided as a trend and thus remain hypothetical.

Interpretation and interrelation of metrics

A recent review on midazolam [15] pointed out that lower level sensory networks show elevated activity levels under weak sedation, what is backed by the observed increase in local connectivity in sensory networks in our study. Analyzing low-frequency fluctuations we found a tendency of increased fALLF values in regions where we detected increased ReHo related to the administration of alprazolam (see Figs. S11, S12, and S13). This could indicate that more homogeneous low-frequency fluctuations due to sedation are in general accompanied by a higher local coherence of the BOLD signal. With ICA we additionally detected an increase in resting-state network coherence in the superior temporal and primary visual cortex. This higher sensitivity of ICA towards changes in within-network connectivity might be attributed to the idea of ICA of decomposing BOLD maps into isolated independent networks. However, with ICA, we did not observe any changes in higher-level networks after administrating alprazolam, while we found a considerable decrease in ReHo in such regions. In higher-level brain networks only considering within-network coherence might be insufficient to capture more complex interactions with other networks. While each rs-fMRI metric captures only one aspect of the complex spatiotemporal dynamics, analyzing multiple metrics simultaneously helps to better preserve the different characteristics of the BOLD signal. While functional whole-brain connectivity reflects global aspects of interactions between brain areas, ReHo and fALFF preserve local characteristics of the BOLD signal. Independent component analysis provides an additional data-driven method to investigate individual resting-state networks. Therefore in an exploratory fMRI study like this, where effects in fMRI are rather unknown, it is beneficial to simultaneously explore the local and global modulations of pharmacological interventions simultaneously.

The loss of global functional connectivity in low-level sensory regions under sedation could relate to several well-known behavioural side effects of alprazolam. Observed modulations in the motor and visual cortices might be connected to motor coordination impairments and visualspatial and visuomotor abilities related to benzodiazepines [51–53]. The decrease of global and local connectivity in high-level region might be connected to impairments in cognitive domains such as attention, working memory and semantic processing, which are affected by long-term treatments with benzodiazepines [54, 55].

Corresponding to the behavioural assessments in the etifoxine condition we did not find significant alterations in any rs-fMRI metric. Several clinical studies have reported an anxiolytic effect of etifoxine for a patient population, postulating a benzodiazepine comparable efficiency in psychopathological circumstances [7–10]. Therefore, for future studies in this field it might be interesting to investigate the effect of TSPO ligands in rs-fMRI for a clinical cohort of subjects with potentially different neurosteroid levels. Our study so far suggests that the favorable clinical side effect profile of etifoxine can be underpinned by neurophysiological data, as none of the typical rs-fMRI markers of sedation were affected by etifoxine.

Pharmacological mechanisms

The pharmacodynamic properties of etifoxine differ in several aspects from benzodiazepines [56]. Benzodiazepines allosterically bind to GABAA receptors containing the α1, α2, α3 or α5 subunits potentiating postsynaptic inhibition [57]. Etifoxine targets α2 containing GABAA receptors subunits and binds to the translocator protein (TSPO) [6] and enhances neurosteroidogenesis [58, 59]. Although changes in GABAergic signalling have been demonstrated in vitro within 1 h [58, 59] of direct application of etifoxine, the treatment duration of 5 days in our study may still have limited the substance effects. The formation of neurosteroids by etifoxine could account for a different effect profile in the brain, as neurosteroids not only affect phasic inhibition via synaptical GABAA receptors, but even more tonic inhibition via extrasynaptic delta subunits containing GABAA receptors [57, 60]. Neurosteroids are even more prone to exert tonic inhibition and the corresponding receptors are expressed mainly within the cerebellum, thalamus and hippocampus [61]. As such, although both substances are believed to act on the GABA neurotransmitter system, their basic differences in target structures and dynamically reflect the differences in their impact on neurophysiological measures like functional connectivity. A specific network stabilization against perturbations or pathological set point alterations, e.g., by tonic postsynaptic GABAergic activity, might explain the lack of resting-state network activity effects of etifoxine in healthy participants. In fact, a concordant picture could be drawn by the use of transcranial magnetic stimulation measures examining etifoxine and alprazolam effects in our group [62].

Conclusion

Comparing etifoxine and alrapzolam in rs-fMRI and studying their effects by combining complementary analysis strategies allowed us to understand neural correlates of sedative side effects in greater detail. The observed decrease in global connectivity and the increase in local connectivity in low-level sensory regions support the idea of a reduction in global integration and sensory network decoupling under sedation. In addition, the absence of sedation-typical behavioural and neurophysiological side effects of etifoxine supports the concept of neurosteroidogenic compounds as psychopharmacological agents for the treatment of anxiety and depression.

Supplementary information

Supplement 1

Supplement 2

Supplementary information

The online version contains supplementary material available at 10.1038/s41386-024-01884-5.

Author contributions

JS, RR, and CN designed the study. RR and CN were responsible for the clinical study. MR, PS, LMB, VW, and JS acquired the imaging data. SW and JS analyzed the imaging data. MR, LMB, and SW analyzed the behavioural data. SW, MR, and JS wrote the initial draft.

Funding

This work has been supported by the German Research Foundation (Deutsche Forschungsgemeinschaft) (DFG), project number 422179811, to JS, RR, CN and within the framework of FOR2858. Open Access funding enabled and organized by Projekt DEAL.

Data availability

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

SW, MR, LMB, PS, VW, CN, and JS declare no conflicts of interest. RR has served as a consultant for Biogen and SAGA Therapeutics.

Ethics approval and consent to participate

The study was approved by the local ethics committee (approval number 18-1197-111) and the National Institute for Pharmaceutical Security (BfArM, Eudra-CT-number: 2018-002181-40). All participants gave their written informed consent at the beginning of the experiment.

1 https://fmriprep.org/en/stable/.

2 https://github.com/martahedl/Updated-atlas-for-corresponding-brain-activation-during-task-and-rest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Olsen RW GABAA receptor: positive and negative allosteric modulators Neuropharmacology 2018 136 10 22 10.1016/j.neuropharm.2018.01.036 29407219
Olsen RW. GABAA receptor: positive and negative allosteric modulators. Neuropharmacology. 2018;136:10–22.29407219 10.1016/j.neuropharm.2018.01.036
2. Poisbeau P Gazzo G Calvel L Anxiolytics targeting GABAA receptors: insights on etifoxine World J Biol Psychiatry 2018 19 S36 S45 10.1080/15622975.2018.1468030 30204559
Poisbeau P, Gazzo G, Calvel L. Anxiolytics targeting GABAA receptors: insights on etifoxine. World J Biol Psychiatry. 2018;19:S36–S45.30204559 10.1080/15622975.2018.1468030
3. Rapoport M Lanctot K Bédard M Vingilis E Murray B Schaffer A Benzodiazepine use and driving J Clin Psychiatry 2009 70 663 73 10.4088/JCP.08m04325 19389334
Rapoport M, Lanctot K, Bédard M, Vingilis E, Murray B, Schaffer A, et al. Benzodiazepine use and driving. J Clin Psychiatry. 2009;70:663–73.19389334 10.4088/JCP.08m04325
4. Sadock J, Sadock A, Ruiz P. Kaplan and Sadock’s comprehensive textbook of psychiatry. In: Kaplan and Sadocks comprehensive textbook of psychiatry. Wolters Kluwer; 2017. https://books.google.de/books?id=gsDljwEACAAJ.
5. Edinoff A Nix C Hollier J Sagrera C Delacroix B Abubakar T Benzodiazepines: uses, dangers, and clinical considerations Neurol Int 2021 13 594 607 10.3390/neurolint13040059 34842811
Edinoff A, Nix C, Hollier J, Sagrera C, Delacroix B, Abubakar T, et al. Benzodiazepines: uses, dangers, and clinical considerations. Neurol Int. 2021;13:594–607.34842811 10.3390/neurolint13040059
6. Rupprecht R Papadopoulos V Rammes G Baghai TC Fan J Akula N Translocator protein (18 kDa)(TSPO) as a therapeutic target for neurological and psychiatric disorders Nat Rev Drug Discov 2010 9 971 88 10.1038/nrd3295 21119734
Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. Translocator protein (18 kDa)(TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9:971–88.21119734 10.1038/nrd3295
7. Nguyen N Fakra E Pradel V Jouve E Alquier C Le Guern M-E Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice Hum Psychopharmacol: Clin Exp 2006 21 139 49 10.1002/hup.757
Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern M-E, et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol: Clin Exp. 2006;21:139–49.10.1002/hup.757
8. Deplanque D Machuron F Waucquier N Jozefowicz E Duhem S Somers S Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study Eur Neuropsychopharmacol 2018 28 925 32 10.1016/j.euroneuro.2018.05.011 30135030
Deplanque D, Machuron F, Waucquier N, Jozefowicz E, Duhem S, Somers S, et al. Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study. Eur Neuropsychopharmacol. 2018;28:925–32.30135030 10.1016/j.euroneuro.2018.05.011
9. Micallef J Soubrouillard C Guet F Le Guern ME Alquier C Bruguerolle B A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects Fundamental Clin Pharmacol 2001 15 209 16 10.1046/j.1472-8206.2001.00025.x
Micallef J, Soubrouillard C, Guet F, Le Guern ME, Alquier C, Bruguerolle B, et al. A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects. Fundamental Clin Pharmacol. 2001;15:209–16.10.1046/j.1472-8206.2001.00025.x
10. Stein DJ Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial Adv Ther 2015 32 57 68 10.1007/s12325-015-0176-6 25620535
Stein DJ. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther. 2015;32:57–68.25620535 10.1007/s12325-015-0176-6
11. Meltzer-Brody S Colquhoun H Riesenberg R Epperson CN Deligiannidis KM Rubinow DR Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials Lancet 2018 392 1058 70 10.1016/S0140-6736(18)31551-4 30177236
Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018;392:1058–70.30177236 10.1016/S0140-6736(18)31551-4
12. Gunduz-Bruce H Silber C Kaul I Rothschild AJ Riesenberg R Sankoh AJ Trial of SAGE-217 in patients with major depressive disorder N Engl J Med 2019 381 903 11 10.1056/NEJMoa1815981 31483961
Gunduz-Bruce H, Silber C, Kaul I, Rothschild AJ, Riesenberg R, Sankoh AJ, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019;381:903–11.31483961 10.1056/NEJMoa1815981
13. Vicente B Saldivia S Hormazabal N Bustos C Rubí P Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, non-inferiority trial Psychopharmacology 2020 237 3357 67 10.1007/s00213-020-05617-6 33009629
Vicente B, Saldivia S, Hormazabal N, Bustos C, Rubí P. Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, non-inferiority trial. Psychopharmacology. 2020;237:3357–67.33009629 10.1007/s00213-020-05617-6
14. Zorumski CF Paul SM Izumi Y Covey DF Mennerick S Neurosteroids, stress and depression: potential therapeutic opportunities Neurosci Biobehav Rev 2013 37 109 22 10.1016/j.neubiorev.2012.10.005 23085210
Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev. 2013;37:109–22.23085210 10.1016/j.neubiorev.2012.10.005
15. Wang J Sun P Liang P Neuropsychopharmacological effects of midazolam on the human brain Brain Inform 2020 7 15 10.1186/s40708-020-00116-y 33170396
Wang J, Sun P, Liang P. Neuropsychopharmacological effects of midazolam on the human brain. Brain Inform. 2020;7:15.33170396 10.1186/s40708-020-00116-y
16. Khalili-Mahani N Rombouts SA van Osch MJ Duff EP Car-bonell F Nickerson LD Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: a review of state-of-the-art, challenges, and opportunities for studying brain chemistry Hum Brain Mapp 2017 38 2276 325 10.1002/hbm.23516 28145075
Khalili-Mahani N, Rombouts SA, van Osch MJ, Duff EP, Car-bonell F, Nickerson LD, et al. Biomarkers, designs, and interpretations of resting-state fMRI in translational pharmacological research: a review of state-of-the-art, challenges, and opportunities for studying brain chemistry. Hum Brain Mapp. 2017;38:2276–325.28145075 10.1002/hbm.23516
17. Wei Z Alcauter S Jin K Peng Z Gao W Graph theoretical analysis of sedation’s effect on whole brain functional system in school-aged children Brain Connect 2013 3 177 89 10.1089/brain.2012.0125 23294031
Wei Z, Alcauter S, Jin K, Peng Z, Gao W. Graph theoretical analysis of sedation’s effect on whole brain functional system in school-aged children. Brain Connect. 2013;3:177–89.23294031 10.1089/brain.2012.0125
18. Hashmi JA Loggia ML Khan S Gao L Kim J Napadow V Dexmedetomidine disrupts the local and global efficiencies of large-scale brain networks Anesthesiology 2017 126 419 30 10.1097/ALN.0000000000001509 28092321
Hashmi JA, Loggia ML, Khan S, Gao L, Kim J, Napadow V, et al. Dexmedetomidine disrupts the local and global efficiencies of large-scale brain networks. Anesthesiology. 2017;126:419–30.28092321 10.1097/ALN.0000000000001509
19. Schrouff J Perlbarg V Boly M Marrelec G Boveroux P Van-haudenhuyse A Brain functional integration decreases during propofol-induced loss of consciousness NeuroImage 2011 57 198 205 10.1016/j.neuroimage.2011.04.020 21524704
Schrouff J, Perlbarg V, Boly M, Marrelec G, Boveroux P, Van-haudenhuyse A, et al. Brain functional integration decreases during propofol-induced loss of consciousness. NeuroImage. 2011;57:198–205.21524704 10.1016/j.neuroimage.2011.04.020
20. Blanco-Hinojo L Pujol J Maciá D Martínez-Vilavella G Martín-Santos R Victor P Mapping the synchronization effect of gamma-aminobutyric acid inhibition on the cerebral cortex using magnetic resonance imaging Brain Connect 2021 11 393 403 10.1089/brain.2020.0844 33797949
Blanco-Hinojo L, Pujol J, Maciá D, Martínez-Vilavella G, Martín-Santos R, Victor P, et al. Mapping the synchronization effect of gamma-aminobutyric acid inhibition on the cerebral cortex using magnetic resonance imaging. Brain Connect. 2021;11:393–403.33797949 10.1089/brain.2020.0844
21. Pflanz CP Pringle A Filippini N Warren M Gottwald J Cowen PJ Effects of seven-day diazepam administration on resting-state functional connectivity in healthy volunteers: a randomized, double-blind study Psychopharmacology 2015 232 2139 47 10.1007/s00213-014-3844-3 25539762
Pflanz CP, Pringle A, Filippini N, Warren M, Gottwald J, Cowen PJ, et al. Effects of seven-day diazepam administration on resting-state functional connectivity in healthy volunteers: a randomized, double-blind study. Psychopharmacology. 2015;232:2139–47.25539762 10.1007/s00213-014-3844-3
22. Liang P Zhang H Xu Y Jia W Zang Y Li K Disruption of cortical integration during midazolam-induced light sedation Hum Brain Mapp 2015 36 4247 61 10.1002/hbm.22914 26314702
Liang P, Zhang H, Xu Y, Jia W, Zang Y, Li K. Disruption of cortical integration during midazolam-induced light sedation. Hum Brain Mapp. 2015;36:4247–61.26314702 10.1002/hbm.22914
23. Kiviniemi V Kantola J-H Jauhiainen J Hyvärinen A Tervonen O Independent component analysis of nondeterministic fMRI signal sources NeuroImage 2003 19 253 60 10.1016/S1053-8119(03)00097-1 12814576
Kiviniemi V, Kantola J-H, Jauhiainen J, Hyvärinen A, Tervonen O. Independent component analysis of nondeterministic fMRI signal sources. NeuroImage. 2003;19:253–60.12814576 10.1016/S1053-8119(03)00097-1
24. Kiviniemi VJ Haanpää H Kantola J-H Jauhiainen J Vainionpää V Alahuhta S Midazolam sedation increases fluctuation and synchrony of the resting brain BOLD signal Magn Reson Imaging 2005 23 531 7 10.1016/j.mri.2005.02.009 15919598
Kiviniemi VJ, Haanpää H, Kantola J-H, Jauhiainen J, Vainionpää V, Alahuhta S, et al. Midazolam sedation increases fluctuation and synchrony of the resting brain BOLD signal. Magn Reson Imaging. 2005;23:531–7.15919598 10.1016/j.mri.2005.02.009
25. Greicius MD Kiviniemi V Tervonen O Vainionpää V Alahuhta S Reiss AL Persistent default-mode network connectivity during light sedation Hum Brain Mapp 2008 29 839 47 10.1002/hbm.20537 18219620
Greicius MD, Kiviniemi V, Tervonen O, Vainionpää V, Alahuhta S, Reiss AL, et al. Persistent default-mode network connectivity during light sedation. Hum Brain Mapp. 2008;29:839–47.18219620 10.1002/hbm.20537
26. Seidel P Levine SM Tahedl M Schwarzbach JV Temporal signal-to-noise changes in combined multislice-and in-plane-accelerated echo-planar imaging with a 20-and 64-channel coil Sci Rep 2020 10 1 9 10.1038/s41598-020-62590-y 31913322
Seidel P, Levine SM, Tahedl M, Schwarzbach JV. Temporal signal-to-noise changes in combined multislice-and in-plane-accelerated echo-planar imaging with a 20-and 64-channel coil. Sci Rep. 2020;10:1–9.31913322 10.1038/s41598-020-62590-y
27. Sporns, O. Networks of the brain. Cambridge, MA: MIT Press; 2010.
28. Jiang L Zuo X-N Regional homogeneity: a multimodal, multiscale neuroimaging marker of the human connectome Neuroscientist 2016 22 486 505 10.1177/1073858415595004 26170004
Jiang L, Zuo X-N. Regional homogeneity: a multimodal, multiscale neuroimaging marker of the human connectome. Neuroscientist. 2016;22:486–505.26170004 10.1177/1073858415595004
29. Zou Q-H Zhu C-Z Yang Y Zuo X-N Long X-Y Cao Q-J An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: Fractional ALFF J Neurosci Methods 2008 172 137 41 10.1016/j.jneumeth.2008.04.012 18501969
Zou Q-H, Zhu C-Z, Yang Y, Zuo X-N, Long X-Y, Cao Q-J, et al. An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: Fractional ALFF. J Neurosci Methods. 2008;172:137–41.18501969 10.1016/j.jneumeth.2008.04.012
30. Kiviniemi V Jauhiainen J Tervonen O Pääkkö E Oikarinen J Vainionpää V Slow vasomotor fluctuation in fMRI of anesthetized child brain Magn Reson Med 2000 44 373 8 10.1002/1522-2594(200009)44:3<373::AID-MRM5>3.0.CO;2-P 10975887
Kiviniemi V, Jauhiainen J, Tervonen O, Pääkkö E, Oikarinen J, Vainionpää V, et al. Slow vasomotor fluctuation in fMRI of anesthetized child brain. Magn Reson Med. 2000;44:373–8.10975887 10.1002/1522-2594(200009)44:3<373::AID-MRM5>3.0.CO;2-P
31. Sheehan DV Lecrubier Y Sheehan KH Amorim P Janavs J Weiller E The mini-international neuropsychiatric interview (m.i.n.i.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J Clin Psychiatry 1998 59 22 33 9881538
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The mini-international neuropsychiatric interview (m.i.n.i.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.9881538
32. Manook A Baghai TC Riebel M Nothdurfter C Schwarzbach JV Gessner A Short-term effects of etifoxine on human gut microbiome in healthy men Front Neurosci 2023 17 1188847 10.3389/fnins.2023.1188847 38075272
Manook A, Baghai TC, Riebel M, Nothdurfter C, Schwarzbach JV, Gessner A, et al. Short-term effects of etifoxine on human gut microbiome in healthy men. Front Neurosci. 2023;17:1188847.38075272 10.3389/fnins.2023.1188847
33. Esteban, O, Blair, R, Markiewicz, C J, Berleant, S L, Moodie, C, Ma, F, et al. poldracklab/fmriprep: 1.0.0-rc5. 2017. 10.5281/zenodo.996169.
34. Jenkinson M Bannister P Brady M Smith S Improved optimization for the robust and accurate linear registration and motion correction of brain images NeuroImage 2002 17 825 41 10.1006/nimg.2002.1132 12377157
Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. NeuroImage. 2002;17:825–41.12377157 10.1006/nimg.2002.1132
35. Glasser MF Sotiropoulos SN Wilson JA Coalson TS Fischl B Andersson JL The minimal preprocessing pipelines for the human connectome project NeuroImage 2013 80 105 24 10.1016/j.neuroimage.2013.04.127 23668970
Glasser MF, Sotiropoulos SN, Wilson JA, Coalson TS, Fischl B, Andersson JL, et al. The minimal preprocessing pipelines for the human connectome project. NeuroImage. 2013;80:105–24.23668970 10.1016/j.neuroimage.2013.04.127
36. Glasser M Coalson T Robinson E Hacker C Harwell J Yacoub E A multi-modal parcellation of human cerebral cortex Nature 2016 536 171 8 10.1038/nature18933 27437579
Glasser M, Coalson T, Robinson E, Hacker C, Harwell J, Yacoub E, et al. A multi-modal parcellation of human cerebral cortex. Nature. 2016;536:171–8.27437579 10.1038/nature18933
37. McAuley JJ da Fontoura Costa L Caetano TS Rich-club phenomenon across complex network hierarchies Appl Phys Lett 2007 91 084103 10.1063/1.2773951
McAuley JJ, da Fontoura Costa L, Caetano TS. Rich-club phenomenon across complex network hierarchies. Appl Phys Lett. 2007;91:084103.10.1063/1.2773951
38. Yang H Long X-Y Yang Y Yan H Zhu C-Z Zhou X-P Amplitude of low frequency fluctuation within visual areas revealed by resting-state functional MRI NeuroImage 2007 36 144 52 10.1016/j.neuroimage.2007.01.054 17434757
Yang H, Long X-Y, Yang Y, Yan H, Zhu C-Z, Zhou X-P, et al. Amplitude of low frequency fluctuation within visual areas revealed by resting-state functional MRI. NeuroImage. 2007;36:144–52.17434757 10.1016/j.neuroimage.2007.01.054
39. Mckeown MJ Analysis of fmri data by blind separation into independent spatial components Hum Brain Mapp 1998 6 160 88 10.1002/(SICI)1097-0193(1998)6:3<160::AID-HBM5>3.0.CO;2-1 9673671
Mckeown MJ. Analysis of fmri data by blind separation into independent spatial components. Hum Brain Mapp. 1998;6:160–88.9673671 10.1002/(SICI)1097-0193(1998)6:3<160::AID-HBM5>3.0.CO;2-1
40. Calhoun V Adali T Pearlson G JJ P A method for making group inferences using independent component analysis of functional mri data: Exploring the visual system Neuroimage 2001 13 88 10.1016/S1053-8119(01)91431-4
Calhoun V, Adali T, Pearlson G, JJ P. A method for making group inferences using independent component analysis of functional mri data: Exploring the visual system. Neuroimage. 2001;13:8810.1016/S1053-8119(01)91431-4
41. Beckmann C CE M Filippini N SM S Group comparison of resting-state fMRI data using multi-subject ICA and dual regression Neuroimage 2009 47 S148 10.1016/S1053-8119(09)71511-3
Beckmann C, CE M, Filippini N, SM S. Group comparison of resting-state fMRI data using multi-subject ICA and dual regression. Neuroimage. 2009;47:S148.10.1016/S1053-8119(09)71511-3
42. Wein S Tomé AM Goldhacker M Greenlee MW Lang EW A constrained ICA-EMD model for group level fMRI analysis Front Neurosci 2020 14 493061 10.3389/fnins.2020.00221
Wein S, Tomé AM, Goldhacker M, Greenlee MW, Lang EW. A constrained ICA-EMD model for group level fMRI analysis. Front Neurosci. 2020;14:493061.10.3389/fnins.2020.00221
43. Lu W Rajapakse JC ICA with reference Neurocomputing 2006 69 2244 57 10.1016/j.neucom.2005.06.021
Lu W, Rajapakse JC. ICA with reference. Neurocomputing. 2006;69:2244–57.10.1016/j.neucom.2005.06.021
44. Tahedl, M, Schwarzbach, J V. An automated pipeline for obtaining labeled ICA-templates corresponding to functional brain systems. Hum Brain Mapping 2023;44:5202–5211.
45. Benjamini Y Hochberg Y Controlling the false discovery rate: a practical and powerful approach to multiple testing J R Stat Soc Ser B (Methodol) 1995 57 289 300 10.1111/j.2517-6161.1995.tb02031.x
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol). 1995;57:289–300.10.1111/j.2517-6161.1995.tb02031.x
46. Karolis VR Froudist-Walsh S Brittain PJ Kroll J Ball G Edwards AD Reinforcement of the brain’s rich-club architecture following early neurodevelopmental disruption caused by very preterm birth Cereb Cortex 2016 26 1322 35 10.1093/cercor/bhv305 26742566
Karolis VR, Froudist-Walsh S, Brittain PJ, Kroll J, Ball G, Edwards AD, et al. Reinforcement of the brain’s rich-club architecture following early neurodevelopmental disruption caused by very preterm birth. Cereb Cortex. 2016;26:1322–35.26742566 10.1093/cercor/bhv305
47. Thomas Yeo BT Krienen FM Sepulcre J Sabuncu MR Lashkari D Hollinshead M The organization of the human cerebral cortex estimated by intrinsic functional connectivity J Neurophysiol 2011 106 1125 65 10.1152/jn.00338.2011 21653723
Thomas Yeo BT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol. 2011;106:1125–65.21653723 10.1152/jn.00338.2011
48. Lee J-M Kim P-J Kim H-G Hyun H Kim YJ Kim J-W Analysis of brain connectivity during nitrous oxide sedation using graph theory Sci Rep 2020 10 2354 10.1038/s41598-020-59264-0 32047246
Lee J-M, Kim P-J, Kim H-G, Hyun H, Kim YJ, Kim J-W, et al. Analysis of brain connectivity during nitrous oxide sedation using graph theory. Sci Rep. 2020;10:2354.32047246 10.1038/s41598-020-59264-0
49. Wei J Chen T Li C Liu G Qiu J Wei D Eyes-open and eyes-closed resting states with opposite brain activity in sensorimotor and occipital regions: Multidimensional evidences from machine learning perspective Front Hum Neurosci 2018 12 422 10.3389/fnhum.2018.00422 30405376
Wei J, Chen T, Li C, Liu G, Qiu J, Wei D. Eyes-open and eyes-closed resting states with opposite brain activity in sensorimotor and occipital regions: Multidimensional evidences from machine learning perspective. Front Hum Neurosci. 2018;12:422.30405376 10.3389/fnhum.2018.00422
50. Liu D-Q Dong Z Zuo X-N Wang J Zang Y-F Eyes-open/eyes-closed dataset sharing for reproducibility evaluation of resting state fMRI data analysis methods Neuroinformatics 2013 11 469 76 10.1007/s12021-013-9187-0 23836389
Liu D-Q, Dong Z, Zuo X-N, Wang J, Zang Y-F. Eyes-open/eyes-closed dataset sharing for reproducibility evaluation of resting state fMRI data analysis methods. Neuroinformatics. 2013;11:469–76.23836389 10.1007/s12021-013-9187-0
51. Griffin CE Kaye AM Bueno FR Kaye AD Benzodiazepine pharmacology and central nervous system-mediated effects Ochsner J 2013 13 214 23 23789008
Griffin CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13:214–23.23789008
52. Golombok S Moodley P Lader M Cognitive impairment in long-term benzodiazepine users Psychological Med 1988 18 365 74 10.1017/S0033291700007911
Golombok S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepine users. Psychological Med. 1988;18:365–74.10.1017/S0033291700007911
53. Tata PR Rollings J Collins M Pickering A Jacobson R Lack of cognitive recovery following withdrawal from long-term benzodiazepine use Psychol Med 1994 24 203 13 10.1017/S0033291700026969 8208885
Tata PR, Rollings J, Collins M, Pickering A, Jacobson R. Lack of cognitive recovery following withdrawal from long-term benzodiazepine use. Psychol Med. 1994;24:203–13.8208885 10.1017/S0033291700026969
54. Barker M Greenwood K Jackson M Crowe S Cognitive effects of long-term benzodiazepine use - a meta-analysis CNS Drugs 2004 18 37 48 10.2165/00023210-200418010-00004 14731058
Barker M, Greenwood K, Jackson M, Crowe S. Cognitive effects of long-term benzodiazepine use - a meta-analysis. CNS Drugs. 2004;18:37–48.14731058 10.2165/00023210-200418010-00004
55. Stewart S The effect of benzodiazepines on cognition J Clin Psychiatry 2005 66 9 13 15762814
Stewart S. The effect of benzodiazepines on cognition. J Clin Psychiatry. 2005;66:9–13.15762814
56. Rupprecht R Rammes G Eser D Baghai TC Schüle C Nothdurfter C Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects Science 2009 325 490 3 10.1126/science.1175055 19541954
Rupprecht R, Rammes G, Eser D, Baghai TC, Schüle C, Nothdurfter C, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science. 2009;325:490–3.19541954 10.1126/science.1175055
57. Carver CM Reddy DS Neurosteroid interactions with synaptic and extrasynaptic GABAA receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability Psychopharmacology 2013 230 151 88 10.1007/s00213-013-3276-5 24071826
Carver CM, Reddy DS. Neurosteroid interactions with synaptic and extrasynaptic GABAA receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability. Psychopharmacology. 2013;230:151–88.24071826 10.1007/s00213-013-3276-5
58. Rupprecht, R, Pradhan, A K, Kufner, M, Brunner, L M, Nothdurfter, C, Wein, S, et al. Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options. Eur Arch Psychiatry Clin Neurosci. 2022;273:1–11.
59. Verleye M Akwa Y Liere P Ladurelle N Pianos A Eychenne B The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain Pharmacol Biochem Behav 2005 82 712 20 10.1016/j.pbb.2005.11.013 16388839
Verleye M, Akwa Y, Liere P, Ladurelle N, Pianos A, Eychenne B, et al. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. Pharmacol Biochem Behav. 2005;82:712–20.16388839 10.1016/j.pbb.2005.11.013
60. Belelli D Hogenkamp D Gee KW Lambert JJ Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor Neurobiol Stress 2020 12 100207 100207 10.1016/j.ynstr.2019.100207 32435660
Belelli D, Hogenkamp D, Gee KW, Lambert JJ. Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor. Neurobiol Stress. 2020;12:100207–100207.32435660 10.1016/j.ynstr.2019.100207
61. Pirker S Schwarzer C Wieselthaler A Sieghart W Sperk G GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain Neuroscience 2000 101 815 50 10.1016/S0306-4522(00)00442-5 11113332
Pirker S, Schwarzer C, Wieselthaler A, Sieghart W, Sperk G. GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience. 2000;101:815–50.11113332 10.1016/S0306-4522(00)00442-5
62. Riebel M Pappenheim B Kanig C Nothdurfter C Wetter T Rupprecht R GABAergic effects of etifoxine and alprazolam assessed by double pulse TMS Pharmacopsychiatry 2023 56 154 61 10.1055/a-2078-4823 37220781
Riebel M, Pappenheim B, Kanig C, Nothdurfter C, Wetter T, Rupprecht R, et al. GABAergic effects of etifoxine and alprazolam assessed by double pulse TMS. Pharmacopsychiatry. 2023;56:154–61.37220781 10.1055/a-2078-4823
